- Home
- VTGN vs TNYA Comparison
VTGN vs TNYA Comparison
Compare VTGN & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- TNYA
- Stock Information
- Founded
- VTGN 1998
- TNYA 2016
- Country
- VTGN United States
- TNYA United States
- Employees
- VTGN N/A
- TNYA N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- VTGN Health Care
- TNYA Health Care
- Exchange
- VTGN Nasdaq
- TNYA Nasdaq
- Market Cap
- VTGN 82.7M
- TNYA 74.7M
- IPO Year
- VTGN N/A
- TNYA 2021
- Fundamental
- Price
- VTGN $2.93
- TNYA $1.11
- Analyst Decision
- VTGN
- TNYA Strong Buy
- Analyst Count
- VTGN 0
- TNYA 5
- Target Price
- VTGN N/A
- TNYA $17.50
- AVG Volume (30 Days)
- VTGN 192.7K
- TNYA 1.9M
- Earning Date
- VTGN 02-13-2025
- TNYA 03-17-2025
- Dividend Yield
- VTGN N/A
- TNYA N/A
- EPS Growth
- VTGN N/A
- TNYA N/A
- EPS
- VTGN N/A
- TNYA N/A
- Revenue
- VTGN $698,000.00
- TNYA N/A
- Revenue This Year
- VTGN N/A
- TNYA N/A
- Revenue Next Year
- VTGN N/A
- TNYA N/A
- P/E Ratio
- VTGN N/A
- TNYA N/A
- Revenue Growth
- VTGN N/A
- TNYA N/A
- 52 Week Low
- VTGN $2.22
- TNYA $0.86
- 52 Week High
- VTGN $5.74
- TNYA $7.01
- Technical
- Relative Strength Index (RSI)
- VTGN 53.66
- TNYA 44.41
- Support Level
- VTGN $2.72
- TNYA $1.43
- Resistance Level
- VTGN $3.10
- TNYA $1.12
- Average True Range (ATR)
- VTGN 0.19
- TNYA 0.10
- MACD
- VTGN 0.00
- TNYA 0.05
- Stochastic Oscillator
- VTGN 66.00
- TNYA 65.70
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.